Patients with diabetes mellitus (DM) were more often hypogonadal than normal fasting glucose subjects. The aim of this investigation is the assessment of characteristics and psychobiological correlates of DM associated with hypogonadism (DMAH). The Structured Interview SIEDY r was used along with several biochemical, psychological and instrumental investigations in a series of more than 1200 patients with erectile dysfunction (ED); 16% of whom with type II DM. Hypogonadism was defined as circulating total testosterone (T) below 10.4 nmol/l. The prevalence of hypogonadism was 24.5% in DM versus 12.6% in the rest of the sample (Po0.0001); differences in the prevalence of hypogonadism retained significance after adjustment for age and BMI. DMAH was associated with typical hypogonadism-related symptoms, such as reduction in sexual desire, leading to a decreased number of sexual attempts, and with higher depressive symptomatology. In DMAH, testis size and LH concentrations were significantly reduced, suggesting a central origin of the disease. At penile Duplex ultrasound examination, diabetic patients and in particular hypogonadal type II diabetic patients showed lower levels of basal and dynamic (after PGE 1 injection) peak systolic velocity and acceleration, when compared to the rest of the sample, even after adjustment for age and BMI. Our results show that hypogonadism is frequently associated with type II DM, at least in the 6th decade. DMAH might exacerbate sexual dysfunction by reducing libido and mood and further compromising penile vascular reactivity.
Introduction
As reported by McCulloch et al. 1 in the late 18th century, Rollo suggested that diabetes mellitus (DM) and erectile dysfunction (ED) were quite often associated, although the intimate molecular reasons underlying such an association are still unclear. Autonomic neuropathy and vascular complications are commonly supposed to be responsible for ED in DM. 2 However, the possibility that hypogonadism might contribute to DM-related sexual dysfunction has been reconsidered recently, due to a higher prevalence of a low testosterone in diabetic than in nondiabetic individuals. [3] [4] [5] [6] Several longitudinal studies reported that a lower androgen milieu increased the risk for developing diabetes, [7] [8] [9] [10] although 6 months of androgen supplementation in a small cohort of symptomatic hypogonadal DM type II patients did not ameliorate glycemic control. 6 Recently, it has been reported that androgen deficiency in type II diabetes is commonly associated with a gonadotropin deficiency leading to hypogonadotropic hypogonadism. 4 Until now, the effect of hypogonadism on the psychobiological correlates of ED in diabetic men have not been thoroughly described. We recently developed a new instrument (SIEDY r ) 11 to quantify organic, marital and intrapsychic contributions to the determinism of ED, and we have applied this instrument in diabetic patients with ED. 5 The aim of the present study is the assessment of organic, psychogenic and relational correlates of ED in hypogonadal DM type II subjects.
Patients and methods
A consecutive series of 1246 patients attending for the first time the Outpatient Clinic for sexual dysfunction was studied. Patients with mental retardation, or coming from foreign countries, were excluded. In particular, the exclusion of foreign people was due to the fact that the national version of SIEDY r has not completely validated for foreign subjects. Characteristics of the sample are summarized in Table 1 .
Patients were categorized as affected by DM in the case of an established diagnosis, or when they showed a fasting glucose X126 mg/dl in more than one occasion, if not previously diagnosed. 12 Individuals with diabetes were classified as affected by type I, type II or other forms of diabetes, following current differential criteria. 12 In diabetic patients, retinopathy was diagnosed through fundus oculi examination as described previously; 13 neuropathy was defined as increase of vibratory perception threshold measured at lower extremity with biothensiometer as described previously; 14 microalbuminuria was measured on an overnight sample and defined as albumin excretion rate higher than 20 mg/min.
Patients were interviewed prior to the beginning of any treatment, and before any specific diagnostic procedures, using the SIEDY r Structured Interview. 11 This brief, multidimensional instrument designed for the pathogenetic assessment of ED provides scores for organic, marital and psychopathological factors affecting sexual function, which can be simultaneously present in the same patient. Patients were asked to specify any current pharmacological treatment; drugs listed in Broderick and Foremann 15 were considered capable of interfering with sexual function. Severity of ED was analyzed using SIEDY r Appendix A as described previously. 11 Similarly, hypoactive sexual desire (HSD) was assessed with item #14 and cardiovascular diseases (CVD) with item #4a of SIEDY r . Frequency of sexual intercourses was investigated using standard questions 'How many sexual attempts did you have in the last 3 months?' and ratings 0 (no attempts), 1 (1-2 attempts), 2 (3-7 attempts) and 3 (8 or more attempts).
Patients were asked to complete the Middlesex Hospital Questionnaire (MHQ), modified, 16 a brief self-reported questionnaire for the screening of mental disorders, which provides scores for freefloating anxiety, phobic anxiety, obsessive-compulsive traits and symptoms, hysterical traits and symptoms, somatization and depressive symptoms.
All patients underwent a complete physical examination, with measurement of blood pressure (mean of three measurements 5 min apart, in sitting position, with a standard sphygmomanometer), height, weight and testis volume (Prader orchidometer). Blood samples were drawn in the morning, after overnight fast, for determination of blood glucose (by glucose oxidase method; Aeroset Abbott, Rome, Italy), total and HDL cholesterol, and triglyceride (by automated enzymatic colorimetric method; Aeroset Abbott, Rome, Italy), glycated hemoglobin (only in diabetic patients; HbA1c; high-pressure liquid chromatography method, with 17 In our previous report, 5 we used a 12 nmol/l limit that has been considered one of the less strict criteria to define male hypogonadism. 17 We now restrict our analysis using a more strict cutoff, that is, when circulating total testosterone (T) was below 10.4 nmol/l (300 ng/dl). This is the value below which effects of testosterone substitution on sexual function were more clearly demonstrated, 18, 19 as also reported by a recent meta-analysis. 20 In addition, diagnosis of hypogonadism is often based on both clinical and biochemical parameters, because an isolated subnormal testosterone level did not readily justify a substitution therapy. 17 Concerning clinical criteria, it should be noted that all the patients, by definition, suffer from any degree of sexual dysfunction, hence this hypogonadism-related symptom could not be employed to clinically identify hypogonadal subjects. Other hypogonadal signs such as muscle strength, muscle size and fatfree mass could be substantially biased by the diabetic disease, and therefore they are not really useful. Hence, we selected PSA, which has been considered a practical bioassay of testosterone activity, because it reflects the plastic effect of biologically active androgens on an age-independent receptive tissue. 21 Penile duplex ultrasound (PDU) examination was performed before and 20 min after PGE 1 intracavernous injection (10 mg). The following parameters were considered: (a) in basal condition: peak systolic velocity (vps) and acceleration (acc) and (b) after PGE 1 intracavernous injection (10 mg): peak systolic velocity (vpmax), end diastolic velocity (edv) and resistance index (RI). 22 Data were expressed as mean7s.d. when normally distributed, and as median [quartiles] for parameters with non-normal distribution, unless otherwise specified. Differences among more than two groups were assessed with one-way ANOVA or Kruskal-Wallis test, whenever appropriate. Unpaired two-sided Student's t-tests were used for comparison of means of normally distributed parameters; when distribution could be normalized through logarithmic transformation, the same test was applied to logarithmically transformed data. In all other cases, Mann-Whitney U-test was used for comparisons between groups. Correlations were assessed using Spearman's or Pearson's method, whenever appropriate. Stepwise multiple linear regression was applied for multivariate analysis, categorizing yes/no parameters as dummy 0/1 variables, whenever appropriate. w 2 test was used for comparison of categorical parameters.
All statistical analysis was performed on SPSS for Windows 11.0.
Results
Among the 1246 patients enrolled, 199 (16%) were affected by type II, and 23 (2%) by type I, DM. The diagnosis of diabetes was made at enrolment, on the basis of a fasting glycemia above the threshold of 126 mg/dl, in 23 subjects (1.9%). The characteristics of patients with normal fasting glucose (NFG), type II and type I DM are summarized in Table 1 .
Type II diabetic patients showed lower HDL and higher BMI and triglyceride when compared to the rest of the sample (Table 1 ). These differences were confirmed after adjustment for age and/or BMI (Table 1) . A higher prevalence of CVD and hypertension was observed in patients with type II diabetes when compared to NFG even after adjustment for age and BMI (Table 1) .
Hypogonadism (total testosterone o10.4 nmol/l) was present in 24.5% of type II diabetic patients, versus 12.6% in nondiabetic individuals (Po0.0001). Mean total testosterone levels were significantly lower in type II diabetic patients (14.576.0 versus 16.676.1 nmol/l, respectively; Po0.0001), and this difference retained statistical significance after adjustment for age (B ¼ À1.6470.5 nmol/l and B ¼ À4.7671.3 pmol/l; both Po0.001). Measurement of FT was available in a subset of 46% patients, 20% of whom were affected by type II DM. In this subset, diabetes was associated with significantly lower FT levels (34.971.20 versus 41.9715.0 pmol/l, respectively; Po0.0001); this difference retained statistical significance after adjustment for age (data not shown). No case of hypogonadism was observed among type I diabetic patients, in whom mean T levels were 19.874.9 nmol/l (Po0.05 versus type II diabetic and nondiabetic individuals; Table 1 ). Note that type I diabetic patients were significantly younger than the rest of the sample (Table 1 ) and differences in T plasma levels disappeared after adjustment for age ( Table 1) . The difference in prevalence of hypogonadism between type II diabetic and nondiabetic patients was significant among those aged less than 60 years, and disappeared in elderly subjects (Figure 1) . Accordingly, mean PSA levels were significantly lower in type II diabetic patients aged 50-59 years than in nondiabetic subjects of the same age range (0.7 [0.4-1.2] versus 1.0 [0.6-1.5] ng/ml; Po0.005), but not in elderly individuals (Figure 1) . Applying a multivariate model with diabetes, age and BMI as putative predictors of hypogonadism, low testosterone was associated with higher BMI No differences after adjustment for age were observed in total cholesterol, TSH and PRL levels between NFG, type I and type II diabetic patients ( Table 1) .
Characteristics of type II diabetic patients with and without hypogonadism are summarized in Table 2 . Hypogonadal patients showed a lower duration of diabetes, a higher BMI and triglyceride, and lower HDL cholesterol than the rest of diabetic patients. Moreover, FT levels and mean testicular volume were significantly lower in hypogonadal patients (Figure 2a and b) even after adjustment for age (data not shown). Furthermore, hypogonadism in diabetic patients was associated with lower LH levels ( Table 2) . No correlation was found between LH and BMI, while a significant correlation was observed between BMI and testosterone (r ¼ À0.353; Po0.0001), even after adjustment for age (Adj. r ¼ À0.27; Po0.0001). No other differences in hormonal and biochemical parameters were observed between diabetic patients with and without hypogonadism ( Table 2) .
Among diabetic patients, those with hypogonadism showed a lower prevalence of nephropathy when compared to the rest of the sample (5.9 versus 30%; Po0.05), while no difference was observed in the prevalence of retinopathy and neuropathy (data not shown). No difference was observed in HbA1c levels between hypogonadal and eugonadal diabetic patients ( Table 2) .
No difference was observed in the prevalence of HSD (as explored by question #14 of SIEDY r Structured Interview) as function of patients' age (data not shown). The prevalence of HSD was significantly lower in diabetic patients when compared to the rest of the sample (29.7 versus 37.6%, respectively; Po0.05). Among type II diabetic patients, those with hypogonadism showed a higher prevalence of HSD when compared to the rest of the sample (43.8 versus 28.1%, respectively; Po0.05).
No difference in ED severity as explored by SIEDY r Appendix A was observed between hypogonadal and eugonadal type II diabetic patients (data not shown). The prevalence of patients reporting more than three sexual attempts for a month was significantly lower in type II diabetic patients with hypogonadism aged 50-59 years than in nonhypogonadal diabetic subjects of the same age Figure 1 Prevalence of hypogonadism (testosterone o10.4 nmol/ l) among diabetic (circles) and nondiabetic (triangles) patients and the respective log 10 (PSA) levels as function of patient's age. N ¼ number of patients. *Po0.005. [3] [4] [5] [6] [7] [8] for MHQ-A and MHQ-D respectively; Po0.05). All these differences were confirmed after adjustment for age (data not shown). Among diabetic patients, those with hypogonadism showed higher MHQ-D scores when compared to eugonadal patients (6 [4-8] versus 4 [2] [3] [4] [5] [6] [7] , respectively; Po0.005). No significant differences were observed between diabetic and nondiabetic individuals and between hypogonadal and eugonadal diabetic patients in other MHQ parameters (data not shown). SIEDY r scale 2 score, which explores the relational component of ED, was not significantly different in diabetic patients when compared to the rest of the sample; no differences were observed between hypogonadal and eugonadal type II diabetic patients (data not shown). SIEDY r scale 1 score, which is an index of the organic disturbances underlying ED, was not compared between diabetic and nondiabetic patients, as diagnosis of diabetes contributes to the scale's score.
Discussion
Among patients with ED, type II diabetes is associated with hypogonadism, at least in the 6th decade, confirming our previous report. 5 This result is consistent with the high prevalence of hypogonadism recently reported in an unselected sample of type II diabetic patients. 4 It should be clarified that this study was performed on patients with sexual dysfunction, and its results cannot be extended to a broader population. The difference in testosterone levels between diabetic and nondiabetic patients is mostly evident in the 6th decade, and it disappears afterwards. In fact, in diabetic patients aged more than 60 years, hypogonadism is not more frequent than in their nondiabetic counterparts. The lack of differences between elderly diabetic and nondiabetic patients could be due to a recruitment bias (i.e. elderly diabetic hypogonadal patients could be less likely to seek specialist advice for ED than hypogonadal subjects without diabetes); alternatively, the higher prevalence of hypogonadism in elderly males could render the effect of diabetes on gonadal function less relevant. On the other hand, the lack of allocation of diabetes with hypogonadism in those aged less than 40 years could be due to the fact that most diabetic patients in these age ranges are affected by type I, and not type II, diabetes.
Measurements of FT were not available in all patients enrolled, and the reduction of total testosterone in type II diabetic patients could be Association of hypogonadism and type II diabetes in men G Corona et al theoretically due to a reduction of sex hormone binding globulin; 23 however, the observation in diabetic patients of reduced levels of PSA, that is an index of androgenic action, 21 in the same age ranges in which the difference in the prevalence of hypogonadism is most evident, suggests that the reduction of testosterone levels in patients with diabetes is a real biological phenomenon. In fact, among those patients in whom measurements of FT were available, diabetes was associated with lower hormone levels, supporting the hypothesis of an increased prevalence of hypogonadism in type II diabetes patients.
Among diabetic patients with ED, those with hypogonadism showed significantly lower LH levels in comparison with eugonadal individuals; this means that type II diabetes is associated with hypogonadotropic hypogonadism, as suggested by previous reports. 4 The mechanisms underlying hypogonadotropic hypogonadism in type II diabetes are not completely clear. It should be observed that obesity is associated with hypogonadism and low LH levels; [24] [25] [26] [27] the inverse correlation between testosterone levels and BMI was confirmed in our sample of diabetic patients. However, although type II diabetes is associated with increased adiposity, differences in testosterone levels between diabetic and nondiabetic patients were still significant after adjustment for BMI. Therefore, hypogonadotropic hypogonadism in type II diabetes is only partly explained by excess body fat. The recent observation that metabolic syndrome, which is associated with insulin resistance, is a risk factor for hypogonadism even after adjustment for BMI 10 suggests that insulin resistance could be associated with impaired function of the hypothalamus-pituitary-gonadal axis independently of adiposity. It has been reported that knockout mice lacking neural insulin receptor show a hypogonadotropic hypogonadism with a normal pituitary response to GnRH, showing that the stimulation of insulin receptor in the central nervous system plays a physiologic role in the regulation of male reproductive endocrine function. 28 This is confirmed by the occurrence of hypogonadotropic hypogonadism in streptozotocin-diabetic rats, 29 which show a severe impairment of insulin secretion. It could be speculated that insulin resistance associated with type II diabetes determines a reduction of insulin action in the hypothalamus, leading to hypogonadotropic hypogonadism; in fact, although no specific measurement of insulin sensitivity was performed in the present study, among patients with diabetes, hypogonadal subjects showed lower HDL cholesterol and higher triglyceride levels in comparison with eugonadal individuals, suggesting a greater degree of insulin resistance. [30] [31] [32] [33] On the other hand, crosssectional study on a smaller sample of healthy, nondiabetic men failed to detect any significant association of hypogonadism with decreased insulin sensitivity after adjustment for body fat mass. 34 Therefore, the hypothesis of an association of insulin resistance with hypogonadotropic hypogonadism needs to be confirmed through specifically designed studies.
No reduction in testosterone levels was observed in type I diabetic patients when compared to Association of hypogonadism and type II diabetes in men G Corona et al nondiabetic subjects with ED, in accordance with previous studies. 23 This result is in apparent contrast with the reported hypogonadotropic hypogonadism in streptozotocin-induced diabetes in rats, which is an animal model similar to type I diabetes. 29 However, it should be considered that, unlike diabetic animals, type I diabetic patients are treated with insulin, and therefore have normal or above normal circulating insulin levels; for this reason, it could be speculated that there is no impairment of stimulation of central insulin receptors in type I diabetic individuals, and this is compatible with eugonadism. However, our data are not conclusive and other studies should be performed in order to better specify this point.
It is noteworthy that hypogonadal diabetic patients showed some differences in their clinical features in comparison with eugonadal diabetic individuals with ED. Although hypogonadism was not associated with a greater severity of ED, erectile parameters at PDU were more severely impaired in hypogonadal than in eugonadal diabetic patients; furthermore, hypogonadism in diabetic patients was associated with a greater depressive symptomatology, which could have some implications in the clinical management of ED. [35] [36] [37] Several clinical trials have shown that response to PDE5 inhibitors is less satisfactory in diabetic patients than in other subjects with ED. 38 Although the reasons for this difference in efficacy are presumably complex, it is conceivable that hypogonadotropic hypogonadism associated with type II diabetes could play a relevant role. In fact, androgens stimulate PDE5 expression in corpora cavernosa; 39 hypogonadism is associated with a reduced response of erectile function to PDE5 inhibitors, which is restored by androgen replacement therapy, in different animal models. 39, 40 Recent studies have shown that testosterone replacement therapy enhances the erectile response to sildenafil in previously unresponsive patients with vasculogenic ED and circulating testosterone levels in the low normal range. 41, 42 Specific clinical trials are needed to verify whether testosterone supplementation could enhance the efficacy of PDE5 inhibitors in type II diabetic patients with testosterone in the lower part of the normal range. However, available data suggest that hormone replacement therapy is useful in patients with frank hypogonadism. 17 Considering that hypogonadotropic hypogonadism is frequent in type II diabetic subjects with ED, an appropriate screening for hypogonadism should always be performed in those patients prior to the initiation of a symptomatic treatment with PDE5 inhibitors or other drugs.
